Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancer
Phase 1
- Conditions
- unresectable or recurrent gastric cancer
- Registration Number
- JPRN-UMIN000005007
- Lead Sponsor
- Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion criteria were as follows 1)patients with serious concomitant disease 2)pregnancy 3)lactating 4)hope pregnancy 5)uncontrolled infection 6)cannot stopped steroids or immunosuppressing drug 7)simultaneous or metachronous double cancers 8)unhealed external injury 9)patients with ileus and interstitial lung disease 10)the cases whom the doctors define as inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety and time to progression
- Secondary Outcome Measures
Name Time Method immunological evaluation, anticancer efficacy, accomplishment rate, 1 & 2 years survival rate, median survival time